The influenza A(H1N1)pdm09 ( pH1N1) virus was first identified in 2 individuals with influenza-like illness in California in April 2009 and subsequently caused a global pandemic that was declared over in August 2010 [1] [2] [3] . In April 2009, the California Department of Public Health (CDPH) initiated surveillance for critically ill and fatal cases of pH1N1. The reported morbidity and mortality in California were high, with 2144 persons admitted to an intensive care unit (ICU) and 608 deaths.
Early in the pandemic, prompt initiation of antiviral treatment was recommended for pH1N1 case patients requiring hospitalization, with comorbidity associated with severe disease or complicated illness regardless of previous health status [4] . The only antiviral drugs for treatment of pH1N1 infection have been the neuraminidase inhibitors (NAIs), which prevent the release of progeny viral particles from infected host cells. The available approved formulations of NAIs include enteral oseltamivir phosphate and inhaled zanamivir [5] , investigational intravenous neuraminidase inhibitors (oseltamivir, peramivir, and zanamivir) available through enrollment in clinical trials, and intravenous zanamivir and intravenous oseltamivir available on a compassionate use basis from the manufacturers. During the pandemic, intravenous peramivir was also made available through an Emergency Use Authorization.
NAIs can shorten the duration of influenza when administered early (within 48 hours after illness onset) to healthy outpatients [6] . Early NAI treatment in this population may also decrease the development of serious complications, such as pneumonia, and the need for hospitalization [6] [7] [8] . However, the efficacy and optimal timing of NAI treatment for patients critically ill with influenza have not been clearly established.
In this report, we analyze critically ill and fatal pH1N1 cases reported to the CDPH who were treated with NAIs and compare their survival on the basis of NAI treatment, including timing of treatment initiation.
METHODS
The CDPH instituted mandatory reporting for all Californians who were hospitalized with or died from pH1N1 infection between 3 April and 10 August 2009 and for those who required ICU admission or died between 11 August 2009 and 10 August 2010. For the purposes of this study, a case patient was defined as a California resident who had results from reverse-transcription polymerase chain reaction (RT-PCR) testing of a respiratory specimen that were indicative of pH1N1 and who was hospitalized in an ICU with signs and symptoms of an acute respiratory infection. Testing was performed at local public health laboratories, commercial laboratories, or the state Viral and Rickettsial Disease Laboratory (VRDL). Cases were reported by providers and hospitals to local health jurisdictions (LHJs), which then reported cases to the CDPH. LHJ and CDPH staff abstracted data on demographic characteristics, clinical presentation and hospital course, comorbid conditions, laboratory results and type, dosing and dates of antiviral medications administered from medical records, and autopsy reports when appropriate, using a standardized case report form. Information on the date of collection of respiratory specimens was available for the subset of case patients whose specimens were tested at VRDL. Secondary bacterial coinfection was defined by isolation of bacteria from either a sterile site or lower respiratory tract specimen in conjunction with a new infiltrate on chest radiograph.
Treated and untreated case patients in the ICU were compared with respect to demographic characteristics, clinical characteristics, and underlying risk factors. Case-fatality proportions were determined for case patients, categorized by numbers of days from onset of symptoms to receipt of antiviral therapy, and were compared to proportions for case patients who were never treated with antivirals.
We compared the survival of treated case patients by each day of treatment onset with (1) survival for all untreated case patients and, to explore the influence of case patients dying earlier in illness, with (2) 
RESULTS

Clinical and Epidemiologic Characteristics
From 3 April 2009 through 10 August 2010, 2144 California residents who required intensive care for or died with pH1N1 virus infection were reported. Of these case patients, 1950 (91%) were hospitalized in the ICU, and 194 (9%) died outside of the hospital. A total of 1859 (95%) of the hospitalized case patients had information available on antiviral treatment; of these, 1676 (90%) were treated with NAIs, and 183 (10%) were not.
The demographic and clinical characteristics of the 1859 hospitalized, critically ill case patients are shown in Table 1 . The median age was 37 years (range, 1 week-93 years), 1473 (79%) had a comorbid condition considered by the Advisory Committee on Immunization Practices [5] to increase the risk of severe influenza, and 492 (26%) died. When comparing the 1676 case patients who received NAI treatment to the 183 case patients who did not, NAI-treated case patients were younger (median age, 36 years vs 44 years; P = .011). There was no significant difference between NAI-treated case patients and untreated case patients with regard to the overall proportion with an Advisory Committee on Immunization Practices comorbid condition, although case patients treated with NAIs had a lower prevalence of metabolic disease (P = .03) and a higher prevalence of pregnancy (P = .02). There was no significant difference in NAI-treated case patients as compared to untreated case patients with regard to development of clinical complications such as pneumonia, sepsis, acute renal failure, or secondary bacterial infection or the need for mechanical ventilation. The median times from symptom onset to hospital admission and from hospital admission to ICU admission were 3 days (range, 0-42 days) and 0 days (range, 0-13 days), respectively. The median 
NAI Treatment and Survival
Of the 1676 case patients who received NAI treatment, 1671 (99.7%) received oseltamivir, and 5 (<1%) received other NAI regimens that did not include oseltamivir. Treatment regimens varied greatly by dosing and duration, including 278 (17%) who received double dosing of oseltamivir (150 mg every 12 hours) and 141 (8%) who received oseltamivir plus another antiviral agent. The median time from the onset of symptoms to the start of NAI treatment was 4 days (range, 0-52 days), and the median duration of NAI treatment was 5 days (range, 0-32 days). NAI treatment was associated with survival: 1260 (75%) of 1676 case patients treated with NAIs survived, compared with 107 (58%) of 183 case patients who did not receive an NAI (P ≤ .0001). Case patients treated with NAIs earlier in their illness had a higher proportion of survival (test for trend, P < .0001; Figure 1 ). These trends were also seen in subgroups of children aged 0-17 years (P = .01), pregnant women (P = .03), and adults with obesity (P < .0001).
Compared with all untreated patients, case patients who received NAI treatment up to 5 days after symptom onset were more likely to survive (P < .05 for each day 0-5; Figure 1) . Compared with untreated patients who survived at least to the day after symptom onset when NAIs were first given to treated individuals, case patients who received NAIs up to 4 days after symptom onset were more likely to survive (P < .05 for each day 0-4).
DISCUSSION
We reviewed >1800 critically ill or fatal cases of pH1N1 in California that received NAIs during the 2009 H1N1 pandemic. Case patients who were treated with NAIs were significantly more likely than those who were never treated to survive the episode, with the earliest treatment initiation conveying the most benefit. Treatment ≤5 days after symptom onset was associated with improved survival, compared with nontreatment.
There is strong evidence of the efficacy of NAI treatment for both uncomplicated and complicated influenza when treatment is initiated in the early stages of illness. In randomized placebo-controlled, trials, oseltamivir reduced the duration of uncomplicated seasonal influenza in adult outpatients versus placebo when initiated within 48 hours after onset of symptoms [6] . Early oseltamivir treatment of influenza virus-infected outpatients may also reduce hospitalization, although the evidence is less clear [7] [8] [9] . Virologic studies suggest a strong correlation between viral replication, clinical symptoms, and disease severity, with detection of viral nucleic acid by RT-PCR from respiratory specimens often used as an approximation for the presence of actively replicating influenza virus. In volunteer challenge studies, peak influenza virus shedding from the respiratory tract occurred on day 2 following experimental infection [10] ; likewise, following naturally acquired infection, most viral shedding occurs during the first 2-3 days after illness onset, with trends in symptom scores closely matching changes in concentrations of detected influenza virus [11] . This short duration of shedding is consistent with a brief window of clinical benefit in previously healthy outpatients.
Existing data reviewing the benefit of NAI treatment in hospitalized influenza patients within 48 hours after symptom onset suggest clinical benefit, with the time at which therapy becomes futile being unclear. In 2 large, retrospective, national observational studies of 272 hospitalized adults and children and 509 hospitalized pregnant women in the United States, patients who were treated for A(H1N1)pdm09 infection within 48 hours after illness onset were less likely to require intensive care or die [12, 13] . ICU patients in Argentina and Spain who were critically ill with pH1N1 were more likely to survive if they were treated with NAIs within 24-48 hours after onset [14, 15] . Moreover, initiation of NAIs within 2 days after illness onset in 127 hospitalized patients with highly pathogenic avian influenza A virus (H5N1) infection in Indonesia was associated with significantly lower mortality than delayed initiation [16] .
Treatment initiated >48 hours after symptom onset might also be beneficial for patients with complicated or severe influenza, who, compared with outpatients, shed influenza virus in increased quantity and duration. The median duration of influenza viral shedding in hospitalized case patients has been By using "Never treated" as the reference group, the proportion of case patients who survived when treated on these days is significantly higher, at P < .05. The Cochran-Armitage test for trend was used to assess the time from onset of symptoms to initiation of antiviral treatment and survival (P < .0001). The error bars represent 95% confidence intervals.
reported to be ≥15 days, with children and immunosuppressed patients remaining RT-PCR positive for several months [5, 17, 18] . Shedding of pH1N1 viral RNA has been detected by the CDPH in critically ill case patients up to 56 days after illness onset (H. Guevara, CDPH, unpublished data). In a prospective study of 512 hospitalized adults with seasonal influenza in Toronto and a separate study of 538 hospitalized patients with pH1N1 virus infection in Spain, those for whom oseltamivir treatment was initiated >48 hours after symptom onset were more likely to survive than those who were not treated [19, 20] . A retrospective review of 442 hospitalized patients with pH1N1 virus infection in Mexico found a decreased occurrence and severity of pneumonia in those receiving oseltamivir >48 hours after symptom onset [21] . Several retrospective observational studies have found decreased mortality among hospitalized cases in settings where antiviral treatment was initiated within 4 days after onset of symptoms, including in 50 elderly patients with influenza A (H3N2) virus infection [22] , 754 adults hospitalized for influenza A virus infection in Hong Kong [23] , and nearly 10 000 adults and children hospitalized with pH1N1 virus infection in China [24] ; other benefits included decreased risk of ICU admission, shorter length of hospitalization, and earlier viral clearance. Finally, a review of 308 cases of highly pathogenic avian influenza A (H5N1) virus infection from 12 countries suggested increased survival when oseltamivir treatment was started up to 6-8 days after illness onset [25] .
Our study expands on the existing data by analyzing the largest number of critically ill case patients with pH1N1 virus infection reported to date and by reviewing survival for those who received delayed NAI treatment. We observed the correlation between earlier antiviral treatment and increased probability of survival as others have reported for seasonal influenza, pH1N1, and influenza A (H5N1) [12, 15, 23, 25, 26] ; although numbers were smaller, these trends were also observed in children and pregnant women.
Our observational study design meant that the treated and untreated groups may have varied in clinical severity, as we did not randomize treatment and were not able to adequately measure disease severity to adjust for it in the analysis. The untreated patients may have, on average, been less severely ill than patients treated with NAI, as their average hospital stay was briefer; the decision to treat with NAIs may have been influenced by the clinician's perception of disease severity. While these limitations and potential biases reduce our ability to define a precise therapeutic window, a higher proportion of case patients who were critically ill with or died of pH1N1 virus infection and who started NAIs within 5 days after onset of symptoms survived, compared with those who were never treated, and a higher proportion of those who started NAIs within 4 days after symptom onset survived, compared with untreated case patients who survived to the day of NAI treatment onset in the treated group. Our findings do not exclude the possibility that NAI treatment begun even later in illness may still be beneficial.
Additional limitations are important to note. There was likely underreporting of cases of pH1N1 virus infection ascertained from voluntary passive reporting by clinicians. We were unable to analyze other treatment modalities or clinical complications that may have affected outcomes despite treatment with NAIs; for example, systematic testing for bacterial coinfections was not performed for all cases. Although it is possible that some of these patients may have been infected with oseltamivir-resistant pH1N1 viruses, only 9 of 2260 pH1N1 case patients tested in California during this surveillance period were infected with pH1N1 viruses containing the H275Y mutation in neuraminidase, which confers resistance to oseltamivir (CDPH, unpublished data). Therefore, our results likely reflect treatment of patients with oseltamivir-susceptible influenza virus infection. Finally, the findings apply to critically ill patients; less severely ill hospitalized case patients were not studied. Of note, approximately 10% of all 2144 case patients with pH1N1 virus infection reported to the CDPH died at home. It is possible that these case patients who died at home were less likely to have received antiviral treatment, compared with those who were hospitalized, suggesting missed opportunities. Reasons why these home fatalities were not treated, including possible milder symptoms at presentation as compared to those who were hospitalized, lack of access to care, cultural differences in health-seeking behavior, or presence of unidentified medical conditions associated with complicated influenza, merit further investigation.
The efficacy and optimal timing of NAI drugs in hospitalized patients with influenza has not been adequately assessed in randomized placebo-controlled trials. Current guidelines that strongly recommend antiviral treatment as soon as possible [5] for hospitalized patients with influenza make conducting placebo-controlled clinical trials challenging. In addition, the optimal outcome measures other than survival for assessing antiviral efficacy for severely ill patients are unsettled [27] . Nevertheless, our results add to the existing observational data on the effectiveness of starting antiviral treatment with NAIs in critically ill patients who are well into their disease course, and they provide data suggesting that NAI treatment initiation within 5 days after symptom onset improves survival. The median time from onset of symptoms to hospitalization in our patients was 4 days, suggesting that initiation of NAIs in critically ill patients suspected to have influenza should not be delayed while awaiting testing results. Because of the possibility that untreated case patients were less severely ill than treated cases in our study, further research is needed on whether NAI treatment beyond 5 days after symptom onset may also convey benefit. Additional study of the influence on survival of other aspects of NAI treatment, such as length of treatment, efficacy of higher dosing, and combination NAI regimens, is also merited.
Notes
